DRG Market Assessment 보고서

LaunchTrends®: Inflectra/Remsima (Wave 1) is the first in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima, two…

Vaccines are used to confer protection against a host of bacterial and viral pathogens that cause infections associated with high mortality and/or morbidity. Implementation of vaccination programs…

The TreatmentTrends Crohn’s Disease and Ulcerative Colitis (EU) report explores current trends in the management of CD and UC from the perspective of 250 treating EU5 gastroenterologists. The…

Physician and Payer Perspectives on Biologic Use and Novel Therapeutic Targets in the Treatment of Psoriatic Arthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis…

A Survey of Rheumatologists and Interviews with Payers in the EU5 Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that…

Hospital emergency departments (EDs) are sites where the majority of patients with serious, acute bacterial infections initially seek medical care. As such, these sites often represent the initial…

U.S. Payer and Prescriber Perspectives on Clinical Pathways, Bundled Payments, and Accountable Care Organizations As the U.S. healthcare market faces an avalanche of expensive specialty drugs…

A Survey of Medical Oncologists and Interviews with Payers in the EU5 Hepatocellular carcinoma (HCC), thyroid cancer, gastrointestinal stromal tumor (GIST), and neuroendocrine tumors (NETs) fall…

Overactive bladder (OAB) is a common symptom complex characterized by urinary urgency, incontinence, frequency, and nocturia, which occur in the absence of pathologic or metabolic factors that…

Bladder cancer is one of the ten most common cancers worldwide that can afflict both genders and is the 13th most common cause of death associated with cancer. A mixture of immunotherapy (BCG…

LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved to treat…

How Are U.S. Ophthalmologists Incorporating Newly Approved Products into the Treatment Algorithm and How Receptive Are Payers to These Agents? Until the U.S. approval of Genentech’s Lucentis…